Production of truncated MBD4 protein by frameshift mutation in DNA mismatch repair-deficient cells enhances 5-fluorouracil sensitivity that is independent of hMLH1 status

References

• Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Tangen CM, Ungerleider JS, Emerson WA, Tormey DC, Glick JH, et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 1995; 122(5):321-6; PMID:7847642; http://dx.doi.org/10.7326/0003-4819-122-5-199503010-00001
   PubMed Web of Science ®Google Scholar
• Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Goodman PJ, Ungerleider JS, Emerson WA, Tormey DC, Glick JH, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990; 322(6):352-8; PMID:2300087; http://dx.doi.org/10.1056/NEJM199002083220602
   PubMed Web of Science ®Google Scholar
• Boland CR, Sinicrope FA, Brenner DE, Carethers JM. Colorectal cancer prevention and treatment. Gastroenterology 2000; 118(2 Suppl 1):S115-28; PMID:10868902; http://dx.doi.org/10.1016/S0016-5085(00)70010-2
   PubMedGoogle Scholar
• Carethers JM. Systemic treatment of advanced colorectal cancer – tailoring therapy to the tumor. Ther Adv Gastroenterol 2008; 1:33-42; PMID:21180512; http://dx.doi.org/10.1177/1756283X08093607
   PubMedGoogle Scholar
• Meta-analysis Group In Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol. 1998; 16(1):301-8; PMID:9440757
   PubMed Web of Science ®Google Scholar
• Carethers JM, Smith EJ, Behling CA, Nguyen L, Tajima A, Doctolero RT, Cabrera BL, Goel A, Arnold CA, Miyai K, et al. Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer. Gastroenterology 2004; 126(2):394-401; PMID:14762775; http://dx.doi.org/10.1053/j.gastro.2003.12.023
   PubMed Web of Science ®Google Scholar
• Jover R, Zapater P, Castells A, Llor X, Andreu M, Cubiella J, Balaguer F, Sempere L, Xicola RM, Bujanda L, et al. The efficacy of adjuvant chemotherapy with 5-fluorouracil in colorectal cancer depends on the mismatch repair status. Eur J Cancer 2009; 45(3):365-73; PMID:18722765; http://dx.doi.org/10.1016/j.ejca.2008.07.016
   PubMed Web of Science ®Google Scholar
• Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM, Hamilton SR, Laurent-Puig P, Gryfe R, Shepherd LE, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003; 349(3):247-57; PMID:12867608; http://dx.doi.org/10.1056/NEJMoa022289
   PubMed Web of Science ®Google Scholar
• Hamaya Y, Guarinos C, Tseng-Rogenski SS, Iwaizumi M, Das R, Jover R, Castells A, Llor X, Andreu M, Carethers JM. Efficacy of 5-fluorouracil adjuvant therapy for patients with EMAST-positive stage II/III colorectal cancers. PLoS One 2015; 10:e0127591; PMID:25996601; http://dx.doi.org/10.1371/journal.pone.0127591
   PubMedGoogle Scholar
• Marsischky GT, Kolodner RD. Biochemical characterization of the interaction between the Saccharomyces cerevisiae MSH2-MSH6 complex and mispaired bases in DNA. J Biol Chem 1999; 274(38):26668-82; PMID:10480869; http://dx.doi.org/10.1074/jbc.274.38.26668
   PubMed Web of Science ®Google Scholar
• Carethers JM, Koi M, Tseng-Rogenski S. EMAST is a form of microsatellite instability that is initiated by inflammation and modulates colorectal cancer progression. Genes 2015; 6:185-205; PMID:25836926; http://dx.doi.org/10.3390/genes6020185
   PubMed Web of Science ®Google Scholar
• Acharya S, Wilson T, Gradia S, Kane MF, Guerrette S, Marsischky GT, Kolodner R, Fishel R. hMSH2 forms specific mispair-binding complexes with hMSH3 and hMSH6. Proc Natl Acad Sci USA 1996; 93(24):13629-34; PMID:8942985; http://dx.doi.org/10.1073/pnas.93.24.13629
   PubMed Web of Science ®Google Scholar
• Blackwell LJ, Bjornson KP, Modrich P. DNA-dependent activation of the hMutSalpha ATPase. J Biol Chem 1998; 273(48):32049-54; PMID:9822679; http://dx.doi.org/10.1074/jbc.273.48.32049
   PubMed Web of Science ®Google Scholar
• de Wind N, Dekker M, Claij N, Jansen L, van Klink Y, Radman M, Riggins G, van der Valk M, van't Wout K, te Riele H. HNPCC-like cancer predisposition in mice through simultaneous loss of Msh3 and Msh6 mismatch-repair protein functions. Nat Genet 1999; 23(3):359-62; PMID:10545954; http://dx.doi.org/10.1038/15544
   PubMed Web of Science ®Google Scholar
• Genschel J, Littman SJ, Drummond JT, Modrich P. Isolation of MutSbeta from human cells and comparison of the mismatch repair specificities of MutSbeta and MutSalpha. J Biol Chem 1998; 273(31):19895-901; PMID:9677427; http://dx.doi.org/10.1074/jbc.273.31.19895
   PubMed Web of Science ®Google Scholar
• Habraken Y, Sung P, Prakash L, Prakash S. Binding of insertion/deletion DNA mismatches by the heterodimer of yeast mismatch repair proteins MSH2 and MSH3. Curr Biol 1996; 6(9):1185-7; PMID:8805366; http://dx.doi.org/10.1016/S0960-9822(02)70686-6
   PubMed Web of Science ®Google Scholar
• Umar A, Risinger JI, Glaab WE, Tindall KR, Barrett JC, Kunkel TA. Functional overlap in mismatch repair by human MSH3 and MSH6. Genetics 1998; 148(4):1637-46; PMID:9560383
   PubMed Web of Science ®Google Scholar
• Duckett DR, Drummond JT, Murchie AI, Reardon JT, Sancar A, Lilley DM, Modrich P. Human MutSalpha recognizes damaged DNA base pairs containing O6-methylguanine, O4-methylthymine, or the cisplatin-d(GpG) adduct. Proc Natl Acad Sci USA 1996; 93(13):6443-7; PMID:8692834; http://dx.doi.org/10.1073/pnas.93.13.6443
   PubMed Web of Science ®Google Scholar
• Tajima A, Hess MT, Cabrera BL, Kolodner RD, Carethers JM. The mismatch repair complex hMutS alpha recognizes 5-fluorouracil-modified DNA: implications for chemosensitivity and resistance. Gastroenterology 2004; 127(6):1678-84; PMID:15578504; http://dx.doi.org/10.1053/j.gastro.2004.10.001
   PubMed Web of Science ®Google Scholar
• Tajima A, Iwaizumi M, Tseng-Rogenski S, Cabrera BL, Carethers JM. Both hMutSalpha and hMutSbeta DNA mismatch repair complexes participate in 5-Fluorouracil cytotoxicity. PLoS One 2011; 6(12):e28117; PMID:22164234; http://dx.doi.org/10.1371/journal.pone.0028117
   PubMedGoogle Scholar
• Fischer F, Baerenfaller K, Jiricny J. 5-Fluorouracil is efficiently removed from DNA by the base excision and mismatch repair systems. Gastroenterology 2007; 133(6):1858-68; PMID:18054558; http://dx.doi.org/10.1053/j.gastro.2007.09.003
   PubMed Web of Science ®Google Scholar
• Chung H, Chaudhry J, Lopez, CG, Carethers JM. Cyclin E and histone H3 are regulated by 5-fluorouracil in a DNA mismatch repair-dependent manner. Cancer Biol Ther 2010; 10:1147-56; PMID:20930505; http://dx.doi.org/10.4161/cbt.10.11.13447
   PubMed Web of Science ®Google Scholar
• Iwaizumi M, Tseng-Rogenski S, Carethers JM. DNA mismatch repair proficiency executing 5-fluorouracil cytotoxicity in colorectal cancer cells. Cancer Biol Ther 2011; 12(8):756-64; PMID:21814034; http://dx.doi.org/10.4161/cbt.12.8.17169
   PubMed Web of Science ®Google Scholar
• Iwaizumi M, Tseng-Rogenski S, Carethers JM. Acidic tumor microenvironment downregulates hMLH1 but does not diminish 5-fluorouracil chemosensitivity. Mutat Res 2013; 747-8: 19-27; PMID:23643670; http://dx.doi.org/10.1016/j.mrfmmm.2013.04.006
   PubMed Web of Science ®Google Scholar
• Andersen S, Heine T, Sneve R, Konig I, Krokan HE, Epe B, Nilsen H. Incorporation of dUMP into DNA is a major source of spontaneous DNA damage, while excision of uracil is not required for cytotoxicity of fluoropyrimidines in mouse embryonic fibroblasts. Carcinogenesis 2005; 26(3):547-55; PMID:15564287; http://dx.doi.org/10.1093/carcin/bgh347
   PubMed Web of Science ®Google Scholar
• An Q, Robins P, Lindahl T, Barnes DE. 5-Fluorouracil incorporated into DNA is excised by the Smug1 DNA glycosylase to reduce drug cytotoxicity. Cancer Res 2007; 67(3):940-5; PMID:17283124; http://dx.doi.org/10.1158/0008-5472.CAN-06-2960
   PubMed Web of Science ®Google Scholar
• Kunz C, Focke F, Saito Y, Schuermann D, Lettieri T, Selfridge J, Schär P. Base excision by thymine DNA glycosylase mediates DNA-directed cytotoxicity of 5-fluorouracil. PLoS Biol 2009; 7(4):e91; PMID:19402749; http://dx.doi.org/10.1371/journal.pbio.1000091
   PubMedGoogle Scholar
• Sansom OJ, Zabkiewicz J, Bishop SM, Guy J, Bird A, Clarke AR. MBD4 deficiency reduces the apoptotic response to DNA-damaging agents in the murine small intestine. Oncogene 2003; 22(46):7130-6; PMID:14562041; http://dx.doi.org/10.1038/sj.onc.1206850
   PubMed Web of Science ®Google Scholar
• Hendrich B, Hardeland U, Ng HH, Jiricny J, Bird A. The thymine glycosylase MBD4 can bind to the product of deamination at methylated CpG sites. Nature 1999; 401(6750):301-4; PMID:10499592; http://dx.doi.org/10.1038/45843
   PubMed Web of Science ®Google Scholar
• Petronzelli F, Riccio A, Markham GD, Seeholzer SH, Genuardi M, Karbowski M, Yeung AT, Matsumoto Y, Bellacosa A. Investigation of the substrate spectrum of the human mismatch-specific DNA N-glycosylase MED1 (MBD4): fundamental role of the catalytic domain. J Cell Physiol 2000; 185(3):473-80; PMID:11056019; http://dx.doi.org/10.1002/1097-4652(200012)185:3%3c473::AID-JCP19%3e3.0.CO;2-
   PubMed Web of Science ®Google Scholar
• Petronzelli F, Riccio A, Markham GD, Seeholzer SH, Stoerker J, Genuardi M, Yeung AT, Matsumoto Y, Bellacosa A. Biphasic kinetics of the human DNA repair protein MED1 (MBD4), a mismatch-specific DNA N-glycosylase. J Biol Chem 2000; 275(42):32422-9; PMID:10930409; http://dx.doi.org/10.1074/jbc.M004535200
   PubMed Web of Science ®Google Scholar
• Bader S, Walker M, Hendrich B, Bird A, Bird C, Hooper M, Wyllie A. Somatic frameshift mutations in the MBD4 gene of sporadic colon cancers with mismatch repair deficiency. Oncogene 1999; 18(56):8044-7; PMID:10637515; http://dx.doi.org/10.1038/sj.onc.1203229
   PubMed Web of Science ®Google Scholar
• Riccio A, Aaltonen LA, Godwin AK, Loukola A, Percesepe A, Salovaara R, Masciullo V, Genuardi M, Paravatou-Petsotas M, Bassi DE, et al. The DNA repair gene MBD4 (MED1) is mutated in human carcinomas with microsatellite instability. Nat Genet 1999; 23(3):266-8; PMID:10545939; http://dx.doi.org/10.1038/15443
   PubMed Web of Science ®Google Scholar
• Yamada T, Koyama T, Ohwada S, Tago K, Sakamoto I, Yoshimura S, Hamada K, Takeyoshi I, Morishita Y. Frameshift mutations in the MBD4/MED1 gene in primary gastric cancer with high-frequency microsatellite instability. Cancer Lett 2002; 181(1):115-20; PMID:12430186; http://dx.doi.org/10.1016/S0304-3835(02)00043-5
   PubMed Web of Science ®Google Scholar
• Bader SA, Walker M, Harrison DJ. A human cancer-associated truncation of MBD4 causes dominant negative impairment of DNA repair in colon cancer cells. Br J Cancer 2007; 96(4):660-6; PMID:17285135; http://dx.doi.org/10.1038/sj.bjc.6603592
   PubMed Web of Science ®Google Scholar
• Abdel-Rahman WM, Knuutila S, Peltomaki P, Harrison DJ, Bader SA. Truncation of MBD4 predisposes to reciprocal chromosomal translocations and alters the response to therapeutic agents in colon cancer cells. DNA Repair (Amst) 2008; 7(2):321-8; PMID:18162445; http://dx.doi.org/10.1016/j.dnarep.2007.11.009
   PubMed Web of Science ®Google Scholar
• Meyers M, Wagner MW, Mazurek A, Schmutte C, Fishel R, Boothman DA. DNA mismatch repair-dependent response to fluoropyrimidine-generated damage. J Biol Chem 2005; 280(7):5516-26; PMID:15611052; http://dx.doi.org/10.1074/jbc.M412105200
   PubMed Web of Science ®Google Scholar
• Bellacosa A, Cicchillitti L, Schepis F, Riccio A, Yeung AT, Matsumoto Y, Golemis EA, Genuardi M, Neri G. MED1, a novel human methyl-CpG-binding endonuclease, interacts with DNA mismatch repair protein MLH1. Proc Natl Acad Sci USA 1999; 96(7):3969-74; PMID:10097147; http://dx.doi.org/10.1073/pnas.96.7.3969
   PubMed Web of Science ®Google Scholar
• Carethers JM, Jung BH. Genetics and genetic biomarkers in sporadic colorectal cancer. Gastroenterology 2015; 149:1177-90; PMID:26216840; http://dx.doi.org/10.1053/j.gastro.2015.06.047
   PubMed Web of Science ®Google Scholar
• Ashktorab H, Ahuja S, Kannan L, Llor X, Ellis N, Xicola RM, Adeyinka LO, Carethers JM, Brim H, Nouraie M. A meta-analysis of MSI frequency and race in colorectal cancer. Oncotarget 2016; PMID:2710810; http://dx.doi.org/10.18632/oncotarget.8945
   PubMed Web of Science ®Google Scholar
• Chung H, Young DJ, Lopez C, Le T-AT, Lee JK, Ream-Robinson D, Huang SC, Carethers JM. Mutation rates of TGFBR2 and ACVR2 coding microsatellites in human cells with defective DNA mismatch repair. PLoS One 2008; 3:e3463; PMID:18941508; http://dx.doi.org/10.1371/journal.pone.0003463
   PubMedGoogle Scholar
• Chung H, Chaudhry J, Lai JF, Young DJ, Carethers JM. Flanking nucleotide specificity for DNA mismatch repair-deficient frameshifts within Activin Receptor 2 (ACVR2). Mutat Res 2012; 729:73-80; PMID:22001236; http://dx.doi.org/10.1016/j.mrfmmm.2011.09.009
   PubMed Web of Science ®Google Scholar
• Chung H, Lopez CG, Holmstrom J, Young DJ, Lai JF, Ream-Robinson D, Carethers JM. Both microsatellite length and sequence context determine frameshift mutation rates in defective DNA mismatch repair. Hum Mol Genet 2010; 19:2638-4; PMID:20418486; http://dx.doi.org/10.1093/hmg/ddq151
   PubMed Web of Science ®Google Scholar
• Chung H, Lopez CG, Young DJ, Lai JF, Holmstrom J, Ream-Robinson D, Cabrera BL, Carethers JM. Flanking sequence specificity determines coding microsatellite heteroduplex and mutation rates with defective DNA mismatch repair. Oncogene 2010; 29:2172-80; PMID:20140012; http://dx.doi.org/10.1038/onc.2009.508
   PubMed Web of Science ®Google Scholar
• Jung B, Doctolero RT, Tajima A, Nguyen AK, Keku T, Sandler RS, Carethers JM. Loss of activin receptor type 2 protein expression in microsatellite unstable colon cancers. Gastroenterology 2004; 126:654-59; PMID:14988818; http://dx.doi.org/10.1053/j.gastro.2004.01.008
   PubMed Web of Science ®Google Scholar
• Grigera F, Bellacosa A, Kenter AL. Complex relationship between mismatch repair proteins and MBD4 during immunoglobulin class switch recombination. PLoS One 2013; 8(10):e78370; PMID:24205214; http://dx.doi.org/10.1371/journal.pone.0078370
   PubMedGoogle Scholar
• Cortellino S, Turner D, Masciullo V, Schepis F, Albino D, Daniel R, Skalka AM, Meropol NJ, Alberti C, Larue L, et al. The base excision repair enzyme MED1 mediates DNA damage response to antitumor drugs and is associated with mismatch repair system integrity. Proc Natl Acad Sci USA 2003; 100(25):15071-6; PMID:14614141; http://dx.doi.org/10.1073/pnas.2334585100
   PubMed Web of Science ®Google Scholar
• Wong E, Yang K, Kuraguchi M, Werling U, Avdievich E, Fan K, Fazzari M, Jin B, Brown AM, Lipkin M, et al. Mbd4 inactivation increases Cright-arrowT transition mutations and promotes gastrointestinal tumor formation. Proc Natl Acad Sci USA 2002; 99(23):14937-42; PMID:12417741; http://dx.doi.org/10.1073/pnas.232579299
   PubMed Web of Science ®Google Scholar
• Bader S, Walker M, Harrison D. Most microsatellite unstable sporadic colorectal carcinomas carry MBD4 mutations. Br J Cancer 2000; 83(12):1646-9; PMID:11104560; http://dx.doi.org/10.1054/bjoc.2000.1482
   PubMed Web of Science ®Google Scholar
• Boland CR, Goel A. Microsatellite instability in colorectal cancer. Gastroenterology 2010; 138(6):2073-87. e3; PMID:20420947; http://dx.doi.org/10.1053/j.gastro.2009.12.064
   PubMed Web of Science ®Google Scholar
• Carethers JM, Stoffel EM. Lynch syndrome and Lynch syndrome mimics: the growing complex landscape of hereditary colon cancer. World J Gastroenterology 2015; 21:9253-61; PMID:26309352; http://dx.doi.org/10.3748/wjg.v21.i31.9253
   PubMed Web of Science ®Google Scholar
• Collura A, Lagrange A, Svrcek M, Marisa L, Buhard O, Guilloux A, Wanherdrick K, Dorard C, Taieb A, Saget A, et al. Patients with colorectal tumors with microsatellite instability and large deletions in HSP110 T17 have improved response to 5-fluorouracil-based chemotherapy. Gastroenterology 2014; 146(2):401-11. e1; PMID:24512910; http://dx.doi.org/10.1053/j.gastro.2013.10.054
   PubMed Web of Science ®Google Scholar